相关实验视频

Updated: Jun 8, 2025

Accessing Valuable Ligand Supports for Transition Metals: A Modified, Intermediate Scale Preparation of 1,2,3,4,5-Pentamethylcyclopentadiene

Accessing Valuable Ligand Supports for Transition Metals: A Modified, Intermediate Scale Preparation of 1,2,3,4,5-Pentamethylcyclopentadiene

Published on: March 20, 2017

循环金属化 ((III) - 三甲 ((IV) 碳酸盐 schiff 基复合物的抗癌行为与聚合诱导的排放

Xicheng Liu¹, Yiwei Sun¹, Yuan Gao¹

¹Key Laboratory of Life-Organic Analysis of Shandong Province, Institute of Anticancer Agents Development and Theranostic Application, School of Chemistry and Chemical Engineering, Qufu Normal University, Qufu 273165, China.

Journal of inorganic biochemistry

|November 1, 2024

概括

具有聚合诱导排放 (AIE) 特性的新 (III) - 机能素 (IV) 复合物显示出强大的抗癌活性. 这些由AIE激活的复合物向线粒体,克服A549癌细胞中西斯普拉丁耐药性.

科学领域:

有机金属化学有机金属化学
材料科学材料科学材料科学
癌症研究癌症研究

背景情况:

循环金属化 (III) 和有机 (IV) 碳酸盐复合物显示出抗癌潜力.
聚合引起的火 (ACQ) 阻碍了机制研究;聚合引起的排放 (AIE) 提供了一个解决方案.

研究的目的:

设计和合成AIE激活的循环金属化 ((III) - 三甲 ((IV) 碳酸盐希夫基复合物.
研究它们的抗癌机制,包括亚细胞向和细胞形态.
评估它们对癌细胞的体外抗增殖活性,包括对西斯胺耐药的癌细胞.

主要方法:

合成新型的希夫基复合物,其中包括 (III) 和微 (IV).
在缩溶液和聚合状态下AIE属性的表征.
对A549和A549/DDP细胞进行体内细胞毒性测定.
线粒体向和亡途径分析.

主要成果:

合成的复合物表现出显著的AIE效应.
与单个成分相比,它们显示出增强的体外抗增殖活性.
观察到有效的线粒体向和诱导亡.
对抗抗抗性A549/DDP细胞的活性保持不变.

结论:

由AIE激活的环金属化 (III) - 三乙烯 (IV) 碳酸盐希夫基复合物为抗癌药物开发提供了一个有前途的平台.
这些复合物促进了机制研究,并显示出替代制药的潜在潜力.

关键词:

艾伊,这是一个很好的选择.这是一种抗癌药物.循环金属化 (III) 复合物非类药物其他非类药物有机蛋白 (IV) 化合物这里是船只基地.

更多相关视频

A Novel Technique for Generating and Observing Chemiluminescence in a Biological Setting

A Novel Technique for Generating and Observing Chemiluminescence in a Biological Setting

Published on: March 9, 2017

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

相关概念视频

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...